Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma

Published:2023-06-29 Issue:14 Volume:24 Page:1567-1575
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Takamoto Takeshi¹^ORCID,Maruki Yuta²,Kondo Shunsuke²³^ORCID

Affiliation:

1. Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, Japan

2. Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan

3. Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2023.2229728

Reference77 articles.

1. Hepatocellular carcinoma

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

3. Use of the triaxial microcatheter method in super-selective transcatheter arterial chemoembolisation for hepatocellular carcinoma

4. Survival Outcomes in Patients With Advanced Hepatocellular Carcinoma Treated With Drug-Eluting Bead Chemoembolization

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liver Resection for Hepatocellular Carcinoma: Recent Advances;Journal of Clinical and Experimental Hepatology;2025-01

2. Opportunities and challenges of multidisciplinary conversion therapy in advanced hepatocellular carcinoma;Current Cancer Reports;2024-09-11

3. Liver Resection and Transplantation in the Era of Checkpoint Inhibitors;JHEP Reports;2024-08

4. Pathological complete response of hepatocellular carcinoma confirmed by conversion hepatectomy following atezolizumab plus bevacizumab therapy: a case report and literature review;Clinical Journal of Gastroenterology;2023-12-10

5. Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma;Journal of Hepatocellular Carcinoma;2023-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3